Ignacio Fernandez Mata

Ignacio Fernandez Mata

Auto-generated profile, based on publicly available information

Ignacio Fernandez Mata

Cleveland Clinic

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2009 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
Ellen SidranskyEllen Sidransky
Ellen Sidransky
MNM.A. Nalls
M.A. Nalls
JAJ.O. Aasly
J.O. Aasly
JAJ. Aharon-Peretz
J. Aharon-Peretz
GAG. Annesi
G. Annesi
SZS.G. Ziegler
S.G. Ziegler
Recent studies indicate an increased frequency of mutations in the gene encoding glucocerebrosidase (GBA), a deficiency of which causes Gaucher's disease, among patients with Parkinson's disease. We aimed to ascertain the frequency of GBA mutations in an ethnically diverse group of patients with Parkinson's disease. Sixteen centers participated in our international, collaborative study: five from the Americas, six from Europe, two from Israel, and three from Asia. Each center genotyped a standard DNA panel to permit comparison of the genotyping results across centers. Genotypes and phenotypic data from a total of 5691 patients with Parkinson's disease (780 Ashkenazi Jews) and 4898 controls (387 Ashkenazi Jews) were analyzed, with multivariate logistic-regression models and the Mantel–Haenszel procedure used to estimate odds ratios across centers. All 16 centers could detect two GBA mutations, L444P and N370S. Among Ashkenazi Jewish subjects, either mutation was found in 15% of patients and 3% of controls, and among non–Ashkenazi Jewish subjects, either mutation was found in 3% of patients and less than 1% of controls. GBA was fully sequenced for 1883 non–Ashkenazi Jewish patients, and mutations were identified in 7%, showing that limited mutation screening can miss half the mutant alleles. The odds ratio for any GBA mutation in patients versus controls was 5.43 across centers. As compared with patients who did not carry a GBA mutation, those with a GBA mutation presented earlier with the disease, were more likely to have affected relatives, and were more likely to have atypical clinical manifestations. Data collected from 16 centers demonstrate that there is a strong association between GBA mutations and Parkinson's disease.

1 April 2005 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
JKJennifer Kachergus
Jennifer Kachergus
IMIgnacio F. Mata
Ignacio F. Mata
MHMary Hulihan
Mary Hulihan
JTJulie P. Taylor
Julie P. Taylor
SLSarah Lincoln
Sarah Lincoln
MTMathias Toft
Mathias Toft

1 May 2006 in Trends in Neurosciences
Verified
Journal Article
Closed access
IMIgnacio F. Mata
Ignacio F. Mata
WWWilliam J. Wedemeyer
William J. Wedemeyer
MFMatthew J. Farrer
Matthew J. Farrer
JTJulie P. Taylor
Julie P. Taylor
KGKathleen A. Gallo
Kathleen A. Gallo

1 February 2013 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
DTDebby W. Tsuang
Debby W. Tsuang
JLJames B. Leverenz
James B. Leverenz
OLOscar L. Lopez
Oscar L. Lopez
RHRonald L. Hamilton
Ronald L. Hamilton
DBDavid A. Bennett
David A. Bennett
CZCyrus P. Zabetian
Cyrus P. Zabetian
Lewy body disease (LBD) encompasses a spectrum of clinicopathologic entities that include Parkinson disease (PD), PD with dementia (PDD), and dementia with Lewy bodies (DLB). Dementia with Lewy bodies and PDD are differentiated from one another based on clinical criteria. Dementia with Lewy bodies is diagnosed when dementia occurs before or concurrently with parkinsonism, whereas in PDD, parkinsonism precedes dementia by at least 12 months.1 Lewy body disease neuropathologic changes (NCs) include classic histologic inclusions (Lewy bodies) and α-synuclein immunopositive neuronal inclusions and processes (Lewy neurites) in partially overlapping regions of the brain. However, the pathologic classification of DLB is complex because some cases show LBDNCs with no or low levels of Alzheimer disease (AD) NCs, which we refer to as pure DLB (pDLB), while many other cases show LBDNCs with coexistent high levels of ADNCs (LBD-AD). Importantly, the pathophysiologic relationship between LBD-AD, pDLB, and PDD has not been delineated, and whether these disorders share common risk factors remains unclear.

28 December 2023 in Nature Genetics
Verified
Journal Article
Open access
PDF file
JKJonggeol Jeffrey Kim
Jonggeol Jeffrey Kim
DVDan Vitale
Dan Vitale
DODiego Véliz Otani
Diego Véliz Otani
MLMichelle Mulan Lian
Michelle Mulan Lian
KHKarl Heilbron
Karl Heilbron
IMIgnacio Mata
Ignacio Mata
Although over 90 independent risk variants have been identified for Parkinson’s disease using genome-wide association studies, most studies have been performed in just one population at a time. Here we performed a large-scale multi-ancestry meta-analysis of Parkinson’s disease with 49,049 cases, 18,785 proxy cases and 2,458,063 controls including individuals of European, East Asian, Latin American and African ancestry. In a meta-analysis, we identified 78 independent genome-wide significant loci, including 12 potentially novel loci (MTF2, PIK3CA, ADD1, SYBU, IRS2, USP8, PIGL, FASN, MYLK2, USP25, EP300 and PPP6R2) and fine-mapped 6 putative causal variants at 6 known PD loci. By combining our results with publicly available eQTL data, we identified 25 putative risk genes in these novel loci whose expression is associated with PD risk. This work lays the groundwork for future efforts aimed at identifying PD loci in non-European populations.

1 October 2016 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
MDMarie Y. Davis
Marie Y. Davis
CJCatherine O. Johnson
Catherine O. Johnson
JLJames B. Leverenz
James B. Leverenz
DWDaniel Weintraub
Daniel Weintraub
JTJohn Q. Trojanowski
John Q. Trojanowski
CZCyrus P. Zabetian
Cyrus P. Zabetian
Although Parkinson disease (PD) is a common neurodegenerative disorder, our understanding of its pathogenesis remains limited, and neuroprotective therapies have been unattainable. Furthermore, the rate of progression of symptoms is highly variable for reasons that are poorly understood.1-3 Genetic and environmental factors likely play a role in modifying the rate of disease progression. The identification of genes that modify the rate of motor and/or cognitive decline could provide targets for the rational development of novel therapies that delay disease onset or slow progression. Individual-level genotypes for such genes might also be important to consider in the design and analysis of interventional trials for PD.